Circio invites to R&D and corporate update webcast on 26 February 2026

* CEO Dr. Erik D Wiklund will provide a corporate update following the recently completed financing transactions * CTO Dr. Thomas B Hansen will present new in vivo results demonstrating further validation and strengthening of circVec for gene therapy applications

Oslo, Norway, 19 February 2026 -- Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, invites to a live webcast at 10:00am CET on Thursday 26 February 2026. Circio management will provide a corporate update and present recent in vivo results for the circVec circular RNA expression platform technology.

The webcast will feature an overview of circVec AAV development and include new data showcasing strong performance of circVec in new gene therapy areas, as well as further validation and characterization of previously presented results.

The corporate section will cover a summary of Circio s recently completed, highly successful financing transactions and a business outlook for 2026.

Presenters: CEO Dr. Erik Digman Wiklund CTO Dr. Thomas Birkballe Hansen

Time: 10:00 CET on Thursday 26 February 2026

Click here to access Teams webcast (https://teams.microsoft.com/meet/31333387615034?p=2AsTUx1434hLnCr0FC) Meeting ID: 313 333 876 150 34 Passcode: 8SA24KF2

Questions can be submitted in advance by email to Erik D Wiklund: erik.wiklund@circio.com or directly in the live webcast

A recording of the webcast will be made available on the Circio webpage (http://www.circio.com/)

For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com

Neil Hunter -- Hunter PR Phone: +44 782 125 5568 Email: neiljameshunter@gmail.com

About Circio Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.